GYRE earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -80.38. Updated 2026-07-23.
Gyre Therapeutics (GYRE) Research Hub
Gyre Therapeutics (GYRE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.73 USD (-3.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -80.38, market cap 0.54B. This hub links to the full technical, earnings and options research available for GYRE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.73 USD (-3.17%) |
| 52-week range | 5.62 USD – 7.47 USD |
| Trend regime | Range |
| 14-day RSI | 51.1 (Neutral) |
| Trailing P/E | -80.38 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for GYRE
Covered Call on GYRE: how it works, illustrative setup around the real 6.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GYRE: how it works, illustrative setup around the real 6.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GYRE: how it works, illustrative setup around the real 6.73 USD price, max profit/loss, breakeven and when to use it. Educational.
GYRE technical analysis: range, last 6.73 USD, RSI 51.1, 52w range 5.62 USD–7.47 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GYRE in?
Gyre Therapeutics (GYRE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GYRE in an uptrend or downtrend?
As of 2026-09-11, GYRE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GYRE's trailing P/E ratio?
GYRE's trailing P/E is -80.38, with a market cap of 0.54B. See the earnings research page for full valuation detail.
When does GYRE next report earnings?
GYRE is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.08 USD.